Lumos Pharma Inc.

11/21/2024 | Press release | Distributed by Public on 11/21/2024 08:04

Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM 201 to 24 Months in PGHD and Correlation of Growth to LUM 201’s Unique Pulsatile[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.